A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects The primary objective of this clinical trial is to determine the optimal single dose of oral GW679769 when administered in combination with intravenous (IV) ondansetron hydrochloride for the preventio...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures To determine the antiemetic dose of oral GW679769 (0 mg, 50 mg, or 150 mg), when administered for three consecutively days in combination with a single IV dose of ondansetron hydrochloride 4 mg admini...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy Determine the optimal antiemetic dose of oral GW679769 when administered in combination with ondansetron hydrochloride and dexamethasone for the prevention of emesis during the first 120 hours followi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antogonist, GW679769, when administered as 50 mg, 100 mg and 150 mg oral tablets in combination with Ondansetron Hydrochloride and Dexamethasone for the PRevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Moderately Emetogenic Chemotherapy - Determine the optimal dose of oral GW679769 when administered in combination with ondansetron hydrochloride and dexamethasone for the prevention of vomiting during the first 120 hours in subjects re...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Double-blind, Randomised, Multicentre, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients receiving Multiple Cycles of Chemotherapy To evaluate the efficacy of oral SB-497115-GR at doses of 50, 75, and 100 mg compared with placebo in cycle 2 of carboplatin/paclitaxel chemotherapy, administered to subjects with an advanced solid tu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune